Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19413022 | 0.89 | TLR8 (0.32) | NOS2NOS3 | |
| SCHEMBL19413025 | 0.81 | NOS2 (0.35) | NOS2NOS3 | |
| SCHEMBL22030283 | 0.79 | TLR7 (0.37) | NOS2 | |
| SCHEMBL19864001 | 0.79 | TLR7 (0.37) | NOS2 | |
| SCHEMBL22858641 | 0.76 | NOS2 (0.35) | NOS2NOS3 | |
| SCHEMBL22858619 | 0.74 | TLR8 (0.33) | NOS2NOS3 | |
| SCHEMBL30154882 | 0.71 | NOS3 (0.36) | NOS2NOS3 | |
| SCHEMBL4569228 | 0.71 | NOS3 (0.36) | NOS2NOS3 | |
| SCHEMBL23964441 | 0.70 | ALDH1A1 (0.38) | — | |
| SCHEMBL15979318 | 0.68 | ESR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329299-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180044346-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329299-B2 | Heterocyclic compounds and uses thereof | PIK3CA, AKT1, AKT2 | NOS2 1380/4885NOS3 1394/4885 |
| US-20180044346-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NOS2 2455/4885NOS3 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.